Intersect ENT

XENT NASDAQ
20.29
-0.18
-0.88%
After Hours: 20.29 0 0.00% 17:53 07/17 EDT
Open
20.56
Prev Close
20.47
High
20.57
Low
20.22
Volume
380.79K
Avg Vol (3M)
479.92K
52 Week High
35.87
52 Week Low
20.14
% Turnover
1.22%
Market Cap
633.99M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Intersect ENT XENT stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.
MORE >

Recently

Name
Price
%Change